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ABSTRACT
Objective: The aim of this study was to assess the cost-effectiveness of
tenofovir disoproxil fumarate (TDF) in the treatment of chronic hepatitis
B (CHB) versus alternative nucleos(t)ides from a UK National Health
Service (NHS) perspective.
Methods: A Markov model was used to calculate costs and beneﬁts of
nucleos(t)ide strategies in hepatitis B e antigen (HBeAg)-positive and
HBeAg-negative patients with hepatitis B virus mono-infection and com-
pensated liver disease. The model included 18 disease states representing
CHB progression. Quality-of-life data and costs for severe disease states
were based on published studies, while monitoring costs for other disease
states were based on expert opinion. Transition probabilities for move-
ments between states were based on a meta-analysis, clinical trials, and
natural history studies.
Results: First-line TDF generated the highest net beneﬁts of all
211 nucleos(t)ide strategies evaluated at a threshold of £20,000 per
quality-adjusted life-year (QALY) gained. First-line TDF cost £19,084/
QALY gained compared with giving lamivudine (LAM) ﬁrst-line and
switching to TDF when LAM resistance occurs. First-line TDF was also
more effective and less costly than ﬁrst-line entecavir (ETV), and showed
extended dominance over ﬁrst-line adefovir and strategies reserving ade-
fovir, ETV, or combination therapy until after LAM resistance develops.
For patients who have developed LAM resistance, TDF was also the most
cost-effective treatment, generating greater net beneﬁts than any other
second-line strategy.
Conclusions: First-line TDF is the most cost-effective treatment for
patients with CHB at a £20,000 to £30,000/QALY ceiling ratio, costing
£19,084/QALY gained compared with the next best alternative.
Keywords: cost–utility analysis, hepatitis B virus infection, lamivudine, net
beneﬁt approach, nucleoside, nucleotide, tenofovir, Viread.
Introduction
An estimated 326,000 people in the UK are thought to have
chronic hepatitis B (CHB) [1], which can lead to cirrhosis, hepa-
tocellular carcinoma (HCC), and death [2]. Current treatment
options in the UK and Europe include nucleosides (entecavir
[ETV], lamivudine [LAM], and telbivudine [LdT]), nucleotides
(adefovir dipivoxil [ADV] and tenofovir disoproxil fumarate
[TDF]), and interferons (peginterferon-alpha-2a and interferon-
alpha-2a/b).
Although interferons are effective for carefully selected
patients [2], many people do not tolerate treatment [3–5]. A
year’s treatment with peginterferon-alpha-2a leads to hepatitis B
e antigen (HBeAg) seroconversion in approximately 32% of
HBeAg-positive patients, and suppresses viral load to <20,000
copies/mL in around 43% of HBeAg-negative patients [6]; the
remaining patients are likely to require nucleos(t)ides to achieve
sustained viral suppression.
Although nucleos(t)ides are well tolerated, resistance to LAM
arises rapidly, with up to 70% of patients becoming resistant
after 4 years of continuous therapy [7]. Nevertheless, newer
nucleos(t)ides (particularly TDF and ETV) are associated with
substantially lower resistance rates [8–10], and are signiﬁcantly
more effective than LAM or ADV [11–14].
TDF is a nucleotide reverse transcriptase inhibitor with
potency against hepatitis B virus (HBV) [14], including LAM-
resistant HBV [15–17]. In the UK, TDF was licensed for use in
CHB in 2008, although it has been used to treat HIV since 2002.
Recent registration randomized, controlled trials (RCTs) have
shown that TDF is superior to ADV in treatment-naive patients
[14], and is also effective in patients with persistent viremia
during ADV therapy [18]. TDF displays a favorable resistance
proﬁle: no cases of virological HBV resistance have been identi-
ﬁed to date during intensive surveillance, which includes 8 years
of clinical experience in HIV/HBV coinfected patients (who
received TDF alongside other antiretroviral drugs) [16,17,19,20]
and up to 96 weeks of continuous use in controlled clinical trials
on CHB [14,21]. Nevertheless, the cost-effectiveness of TDF in
the treatment of CHB remains to be determined in a UK setting.
We set out to identify the most cost-effective ﬁrst-line nucleo-
s(t)ide treatment for CHB from the perspective of the UK
National Health Service (NHS), and assess which drug(s) should
be given to patients who develop resistance to ﬁrst- or second-
line treatment. This analysis focuses on nucleos(t)ides as they
represent the most commonly used treatments for CHB in the
UK.
Methods
Outline of the Economic Model
A Markov model was constructed to model the progression of
CHB, and the costs and beneﬁts of nucleos(t)ide treatment,
taking account of drug resistance and HBeAg-negative, as well as
HBeAg-positive, CHB. Health beneﬁts were measured in quality-
adjusted life-years (QALYs), which take account of changes in
both length and quality of life.
In addition to calculating the cost per QALY gained, we used
the net beneﬁt approach [22,23] to compare the total monetary
beneﬁts of each treatment with those for all other possible treat-
ment strategies whenever this simpliﬁed the interpretation of
results. Total net beneﬁts are calculated by multiplying the
number of QALYs accrued over a lifetime by the ceiling ratio (the
Address correspondence to: Helen Dakin, Abacus International, 4 Market
Square, Bicester, Oxfordshire OX26 6AA, UK. E-mail: helen.dakin@
abacusint.com
10.1111/j.1524-4733.2010.00782.x
Volume 13 • Number 8 • 2010
V A L U E I N H E A LT H
922 © 2010, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/10/922 922–933
maximum amount that society is willing or able to pay to gain
one QALY) and subtracting the total NHS costs accrued over a
lifetime. The treatment with the highest total net beneﬁt at the
ceiling ratio of interest is the optimal choice for managing that
population and will always correspond to the treatment that is
optimal based on the cost-effectiveness ratio approach.
TotalNetBenefit QALYs CeilingRatio
Cos
TreatmentX TreatmentX= ⋅
− tTreatmentX
The National Institute for Health and Clinical Excellence
(NICE) generally considers treatments costing less than £20,000
to £30,000 per QALY gained to be cost-effective [24]. Net ben-
eﬁts were therefore calculated at ceiling ratios of £20,000 and
£30,000 per QALY; results at a £10,000/QALY threshold are
also presented to test the impact of using a lower ceiling ratio.
The analysis was based on a heterogeneous cohort of
nucleos(t)ide-naive adults (aged 18 years) with compensated
CHB, detectable HBV DNA, and evidence of active liver disease
for whom nucleos(t)ide therapy is considered appropriate.
CHB was deﬁned as persistence of hepatitis B surface antigen
(HBsAg) for at least 6 months. Patients coinfected with HIV or
hepatitis C were excluded. Based on an audit conducted by the
authors of this article in which anonymized hospital records
of 85 HBsAg-positive adults attending a London hepatology
outpatient clinic were reviewed [25], it was assumed that 5.3%
of the patients were cirrhotic at baseline, and that 50% of cir-
rhotic patients and 55.5% of non-cirrhotic patients had HBeAg-
negative CHB. Additional details on this audit are available on
request.
Disease progression was modeled as movements between 18
disease states (Fig. 1). Treatments that slow disease progression
were assumed to reduce disease management costs and extend
patients’ healthy life expectancy, and may therefore be cost-
effective compared with less potent drugs. Furthermore, drug
resistance may increase the risk of disease progression; subse-
quently, treatments with higher resistance rates may be less
cost-effective. Each year, patients were assumed to move
between disease states based on the transition probabilities
shown in Appendix 1 at: http://www.ispor.org/Publications/
value/ViHsupplementary/ViH13i8_Dakin.asp. A lifetime time
horizon was used in the model; because the mean age of
patients in the London clinic audit was 38, of whom 63% were
men, the model was run over a 42-year time horizon (the life
expectancy of this age group [26]).
As resistance to drugs such as LAM develops rapidly [7,27],
it is important to consider second-line (or third-line) treatment
options that are used after resistance develops. The model
allowed for switches between nucleos(t)ide therapies following
development of drug resistance. Patients were assumed to receive
Figure 1 Patient ﬂow diagram for the Markov model.The model uses a 1-year cycle length, such that patients may move between disease states along the arrows
shown once each year. Patients enter the model in one of the four states with a bold black border; as stated in the text, 5.3% of the patients were assumed to be
cirrhotic at baseline,with 50% of cirrhotic patients and 55.5% of noncirrhotic patients having HBeAg-negative CHB.Patients in the disease states shown in white ovals
will be indicated for any treatments available in the relevant treatment strategy.Although patients in the states indicated by * would not be eligible to start therapy
with one or more of the agents considered in the analysis, it was assumed that treatment would not be discontinued if they entered these states after the start of
treatment.Viral suppression was deﬁned as HBV DNA <300 copies/mL occurring without seroconversion, generally as a result of antiviral medication. The liver
transplant state encompassed the year of the transplant operation (from 3 months before the operation to 9 months afterward), after which time surviving patients
progress to the post–liver transplant state. CC, compensated cirrhosis; CHB, chronic hepatitis B; c/ml, copies per milliliter; HBeAg, hepatitis B e antigen; HBsAg,
hepatitis B surface antigen; HBV, hepatitis B virus.
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sequences of up to three nucleos(t)ides (or nucleos(t)ide combi-
nations) followed by best supportive care (BSC), which com-
prised monitoring with no antiviral therapy. The nucleos(t)ide
treatments included in the model are shown in Table 1. For
simplicity, only three combination therapies were included
(Table 1), which represented the most plausible combinations for
ADV, ETV, and TDF. It should be noted that the UK license
indications for nucleos(t)ides neither speciﬁcally mention combi-
nation therapy nor advise against use in combination therapy
[28–31]. Nonetheless, in practice, the drug combinations listed in
Table 1 may be considered clinically appropriate.
All sequences of the treatments shown in Table 1 other than
those in which patients will be resistant to their third-line agent
before starting that treatment were considered in the analysis,
giving a total of 211 different treatment strategies for which costs
and beneﬁts were calculated. Nevertheless, for clarity, results are
only presented for 20 treatment pathways that represent the most
cost-effective of each of the main options; results for other strat-
egies are available on request.
Historically, LAM followed by BSC with no antiviral treat-
ment was the only treatment option available, and this strategy
has been shown to be cost-effective [32], although it is no longer
considered clinically appropriate for patients with high levels of
HBV replication because potent second-line agents are now
available [2,33–35]. BSC and LAM followed by BSC were there-
fore included in the analysis to enable assessment of whether
TDF is the most cost-effective strategy out of all plausible nucleo-
s(t)ide strategies (including those no longer used), and to ensure
that TDF is compared against low-cost strategies with proven
cost-effectiveness.
Interferon-alpha and peginterferon-alpha were not consid-
ered as comparators because these are given as short-term initial
options in selected patients rather than maintenance treatments
[2], and are used by less than 10% of patients [12]. LdT was
excluded because it is rarely used in the UK and is not recom-
mended by NICE [36].
The development of drug resistance and switches between
treatments were modeled by duplicating the 18 disease states
shown in Figure 1, such that separate replica sets of these 18
disease states were used for ﬁrst, second, and third-line treat-
ments, fourth-line treatment with BSC, and for the year(s) in
which resistance developed. Separate sets of states were also used
to allow for variations in transition probabilities and resistance
rates over time.
For simplicity, the risk of resistance was assumed to be the
same for all disease states; the resistance rate data used in the
model are described in Appendix 2. Resistance was deﬁned as
 1 log10 copies/mL rise in HBV DNA from nadir. Virological
resistance was assumed to be identiﬁed an average of 1.5 months
after the rise in HBV DNA, because interviews with ﬁve consult-
ant gastroenterologists suggested that levels are monitored quar-
terly in UK clinical practice. During the year in which resistance
developed, patients were therefore assumed to spend 10.5
months with the same risk of progression/improvement as drug-
sensitive treated patients. When viral load rose at 10.5 months,
patients in the “HBeAg-positive/negative viral suppression”
states and the “HBeAg-positive/negative compensated cirrhosis
HBV DNA <300 copies/mL” states were assumed to switch to
the corresponding states for patients with detectable HBV DNA.
For the remaining 1.5 months of the year, patients who devel-
oped resistance were assumed to have the transition probabilities
of untreated patients, before treatment was switched to the next
treatment in the pathway at the start of the next annual cycle. As
there is some evidence that patients are at increased risk of
hepatic ﬂares and/or decompensation after developing LAM
resistance [27], this assumption may bias the analysis slightly in
favor of the treatments with high resistance rates (e.g., LAM),
although this assumption is unlikely to have any signiﬁcant effect
on the results as patients spend only 1.5 months in this state
before starting their new therapy.
The key assumptions used in the analysis are outlined below:
• The analysis was conducted from the perspective of the
NHS [37].
• Costs and beneﬁts were discounted at a rate of 3.5% per
year [37].
• The reference year for costs was 2006/2007.
• A half-cycle correction was applied, whereby patients were
assumed to move between states halfway through each year.
• It was assumed that patients who were initially infected
with HBeAg-positive HBV could only develop HBeAg-
negative CHB from the HBeAg-seroconverted disease state
[38].
• It was assumed that once patients develop HBeAg-negative
CHB (excluding the HBeAg-seroconverted carrier state),
they could not move back to any HBeAg-positive disease
state.
• Patients were assumed to continue treatment for an average
of 5.6 (range: 0–9) months after HBsAg seroconversion,
and 10.2 (range: 6–12) months after HBeAg seroconver-
sion, based on estimates by four UK clinicians.
• Transition probabilities were assumed to be constant over
time, except for the probability of HBeAg seroconversion,
viral suppression, and reversion from decompensated to
Table 1 Nucleos(t)ide treatments included in the model and their respective daily dosages and costs
Drug Dose Drug cost
BSC (no antiviral therapy) — £0.00/patient-day
LAM (Zefﬁx, GSK) 100 mg/day £2.79/patient-day [5]
TDF* (Viread, Gilead Sciences) 300 mg/day £8.50/patient-day [5,66]
ADV (Hepsera, Gilead Sciences) 10 mg/day £10.50/patient-day [5]
TDF* plus LAM 300 mg/day TDF
100 mg/day LAM
£11.29/patient-day [5,66]
ETV (Baraclude, BMS) 0.5 mg/day for treatment-naive patients and
1 mg/day for patients resistant to 1 nucleos(t)ide
£12.60/patient-day for both doses [5]
ADV plus LAM 10 mg/day ADV
100 mg/day LAM
£13.29/patient-day [5]
ETV plus ADV 10 mg/day ADV
0.5 mg/day ETV for treatment-naive patients and
1 mg/day for patients resistant to 1 nucleos(t)ide
£23.10/patient-day [5]
*300 mg tenofovir disoproxil fumarate (TDF) is equivalent to 245 mg tenofovir disoproxil (as fumarate).
ADV, adefovir; BSC, best supportive care; ETV, entecavir; LAM, lamivudine;TDF, tenofovir disoproxil fumarate.
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compensated cirrhosis, which were assumed to be higher
in the ﬁrst year of treatment than subsequent years (see
Appendix 1 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Dakin.asp).
• Resistance rates were assumed to vary over the ﬁrst ﬁve
years of treatment with any given therapy, and remain
constant at the year 5 values for all subsequent years (see
Appendix 2 at: http://www.ispor.org/Publications/value/
ViHsupplementary/ViH13i8_Dakin.asp).
• HBeAg seroconversion was assumed to have the same out-
comes regardless of whether the patient had previously been
cirrhotic. Nevertheless, movement directly from the
HBeAg-seroconverted state to compensated cirrhosis was
permitted because this has been observed in natural history
studies [32,39–41].
• Because literature reviews identiﬁed no papers quantifying
the costs, utilities, and transition probabilities for patients
with both HCC and decompensated cirrhosis, it was
assumed that patients with HCC could not undergo hepatic
decompensation and that preexisting hepatic decompensa-
tion did not affect outcomes, costs, or quality of life in
HCC; this simpliﬁcation is unlikely to affect the results as
only 1.2% to 1.6% of life-years experienced by the cohort
are spent in the HCC state.
• In cases where two nucleos(t)ides were used in combination,
it was assumed (given a shortage of published data) that the
probability of viral suppression or HBeAg seroconversion
with any combination therapy was equal to that of the most
effective component of that combination, because RCTs
conducted to date do not suggest that combination therapy
increases viral suppression [18,42,43].
• It was conservatively assumed that nucleos(t)ide treatment
does not affect the probability of HBsAg seroconversion
because few trials identiﬁed in a systematic review [11]
reported data on HBsAg seroconversion. Nevertheless, this
assumption may bias the analysis against TDF, which has a
higher incidence of HBsAg seroconversion than ADV in
HBeAg-positive patients [44].
• For the decompensated cirrhosis, liver transplant, and post–
liver transplant disease states, data on total mortality
(including deaths from causes other than hepatitis B) were
used in the model, and no all-cause mortality was applied;
for other disease states, the annual risk of all cause mortal-
ity [26] was added to the excess mortality associated with
the disease state in question to give the total risk of death
each year (see Appendix 1 at: http://www.ispor.org/
Publications/value/ViHsupplementary/
ViH13i8_Dakin.asp).
• Nucleos(t)ides were conservatively assumed to have no
impact on mortality in patients with HCC or compensated
cirrhosis.
• The (generally mild [28–31]) adverse events associated with
nucleos(t)ides were assumed to have no effect on costs,
mortality, or quality of life, although the cost of renal
monitoring was included in the analysis (Table 2). The cost
of osteopenia monitoring was excluded as this is not rou-
tinely conducted in UK clinical practice [28–31].
Further technical details about the model are available from
the authors on request.
Data Sources Used in the Analysis
The majority of model inputs were based on studies identiﬁed in
a systematic literature review of all nucleos(t)ide therapies [11].
Additional literature searches were conducted to identify studies
on the natural history of CHB.
All studies identiﬁed in the systematic review that reported
the incidence of drug resistance over at least 1 year’s follow-up
were pooled to generate overall estimates of the annual risk of
developing resistance to each medication (see Appendix 2
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Dakin.asp). Trials on LAM-resistant patients
[15,45–52] were analyzed separately from those on
nucleos(t)ide-naive patients (see Appendix 2). Nevertheless, resis-
tance rates calculated from studies on LAM-resistant patients
were also applied to patients who were resistant to nucleos(t)ides
other than LAM.
Although no cases of virological resistance to TDF have been
observed to date, experience with older nucleos(t)ides suggests
that drug resistance may eventually be observed. To enable cal-
culation of resistance rates for TDF and for other drugs where no
resistance was observed in any particular year, it was assumed
that the next patient to be treated and monitored would develop
virological resistance. For example, because 0% (0/130) of LAM-
resistant patients receiving TDF at year 1 developed resistance
(see Appendix 2), the highest that the incidence of resistance with
TDF can be is 0.76% (1/131). The resistance rates calculated in
this way therefore represent the maximum rates that we can
expect to see given available evidence and are subsequently likely
to overestimate the actual risk of resistance.
Transition probabilities for the key transitions that differ
between active treatments (the probability of achieving undetect-
able HBV DNA or HBeAg seroconversion with each nucleo-
s(t)ide therapy or nucleos(t)ide combination) were based on a
Table 2 Frequency and cost of consultations for patients in precirrhotic
disease states
Disease state
Mean (range)
no. consultations
per year
Cost per
consultation*
(range)
Active CHB or viral
suppression (treated)
3.3 (2, 4) £114.69 (£46.23, £236.95)
Active CHB or viral
suppression (untreated)
2.8 (1, 4) £121.21 (£16.12, £251.26)
HBeAg seroconverted 2.0 (1, 4) £121.21 (£16.12, £251.26)
HBsAg seroconverted 0.03 (0, 1) £121.21 (£16.12, £251.26)
Number of additional
consultations required in
the year when resistance
develops†
1.17 (0.5, 2) £114.69 (£46.23, £236.95)
Number of additional
consultations required in
year 1 (excluding the
consultation in which
treatment is initiated)
1 (1, 1) £240.60 (£6.25, £742.04)
*The cost per consultation includes the cost of staff, clinic overheads, and laboratory tests
such as full blood count, liver function proﬁle, and HBV DNA quantiﬁcation by polymerase
chain reaction (PCR).All treated patients were assumed to receive quarterly renal monitor-
ing (urea and electrolytes) and, where appropriate, testing for the presence of HBeAg, HBe
antibody, and/or HBsAg.The total cost of tests/investigations was calculated by multiplying
the unit cost per test by the proportion of consultations in which particular tests are
conducted (which was estimated by clinicians) and summing across all tests. In line with its
product license [29], TDF-treated patients were assumed to receive renal monitoring (as-
sumed to comprise urea and electrolyte tests on blood samples taken in practice nurse
consultations) every 4 weeks in their ﬁrst year of treatment, rather than the quarterly
monitoring assumed for all other treated patients. It was assumed that patients would not
receive bone scans, because no clinicians interviewed felt that these would be conducted
routinely.
†In addition to the cost of a consultation, 33% (range: 0–100%) of patients developing drug
resistance were assumed to receive HBV sequencing in the year resistance developed.
The numbers of consultations/patient-year are based on the mean (and range) of estimates
from ﬁve gastroenterologists working in the UK. Full details of the unit costs and quantities
used in the analysis are available on request.
CHB, chronic hepatitis B; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen;
HBV, hepatitis B virus;TDF, tenofovir disoproxil fumarate.
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mixed treatment comparison meta-analysis conducted by the
authors, which is described in the accompanying paper [11].
Transition probabilities for untreated patients were based on
data from natural history studies, economic evaluations, or the
placebo arms of meta-analyses or RCTs (see Appendix 1 at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH13i8_Dakin.asp).
For some of the transitions that may be inﬂuenced by treat-
ment (predominantly those affecting patients with severe liver
disease), data were only available for ADV or LAM. In these
cases, all treated patients were assumed to have the same chance
of improvement/progression regardless of which nucleos(t)ide
was used.
Because the cost of managing severe liver disease is likely to
differ little between hepatitis B and C, costs for the compensated
cirrhosis, decompensated cirrhosis, HCC, liver transplant, and
post–liver transplant disease states were based on large, retro-
spective UK microcosting studies on patients with hepatitis C
[53–55] (Table 3). Costs were inﬂated to 2006/2007 values [56],
and the cost of hepatitis B immunoglobulin was included in the
cost of liver transplantation and posttransplant follow-up. The
cost of nucleos(t)ide therapy was also added where applicable.
The cost of managing patients in other disease states was
based on clinicians’ estimates of the frequency of outpatient
consultations for each patient group and the tests that would be
performed at each consultation (Table 2), which were derived
from telephone interviews with ﬁve consultant gastroenterolo-
gists. The resources used in each consultation were valued, based
on published sources [56,57] and provider tariffs, to produce the
total consultation costs shown in Table 2. Further details on unit
costs and resource use quantities are available on request.
Health state preference values or utilities for most disease
states were based on standard gamble valuations of each health
state from a study involving 93 UK patients with CHB [58,59]
(Table 4). It was conservatively assumed that achieving undetect-
able HBV DNA (in the absence of seroconversion) would not
improve quality of life. The quality of life of HBsAg-
seroconverted patients was based on UK population norms [60];
however, the utility of patients in the HBeAg-seroconverted state
was assumed to be 1% lower than populations norms, based on
a previous economic evaluation [61].
All model parameters other than unit costs were varied inde-
pendently over the range of values that they could plausibly take
in one-way sensitivity analyses. We also conducted probabilistic
Table 3 Disease management costs for severe liver disease
Disease state
No. pts included
in mean cost
Cost per patient or patient-year
(inﬂated to 2006/2007 values using HCHS [56])
Mean cost Lower 95% CI Upper 95% CI
Compensated cirrhosis: cost/patient-year [55] 115 £1,341 £807 £1,876
Decompensated cirrhosis: cost/patient-year [55] 40 £10,750 £7,240 £14,261
HCC: cost/patient-year [55] 20 £9,580 £5,167 £13,992
Liver transplant: cost/patient for waiting list phase lasting 3 months [55] 67 £4,393 £2,604 £6,182
Liver transplant: cost of transplant operation per patient (excluding HBIg) [55] 67 £32,215 £25,550 £38,880
Liver transplant: cost/patient for ﬁrst 8 months’ posttransplant follow-up
(excluding HBIg) [55]
67 £7,432 £3,508 £11,357
Liver transplant: cost/patient for HBIg during year of transplant* — £16,250 £13,750 £18,750
Total cost/patient for liver transplant (over 12 months) — £60,291 — —
Post–liver transplant: cost per patient-year (excluding HBIg) [55] 67 £1,633 £812 £2,453
Post–liver transplant: HBIg in posttransplant: cost per patient-year* — £5,000 — —
Total cost of posttransplant state per patient-year — £6,333 — —
*Cost of HBIg was based on personal communications with a UK transplant center.
CI, conﬁdence interval; HCHS, Hospital and Community Health Services; HCC, hepatocellular carcinoma; HBIg, hepatitis B immunoglobulin.
Table 4 Utilities used in the economic evaluation
State Mean
Lower
95% CI
Upper
95% CI Reference
HBsAg seroconverted 0.86 0.85 0.87 Age-dependent population norm for all ages, based on a representative sample of
3395 members of the UK general population [60]
HBeAg seroconverted 0.85 — — Age-dependent population norm multiplied by 0.99 (an adjustment for presence of
HBsAg based on Wong et al. [61]).The quality of life of the general population
was varied over its 95% CI, while the disutility associated with detectable
HBsAg was varied between 0% and 15% in sensitivity analyses, but was not
varied in PSA.
Active CHB 0.77 0.71 0.81 Ossa et al. [58]*
Viral suppression 0.77 0.71 0.81 Assumed to be the same as for active CHB
Compensated cirrhosis, HBV
DNA-negative
0.73 0.65 0.77 Ossa et al. [58]*
Compensated cirrhosis, HBV
DNA-positive
0.73 0.65 0.77 Assumed to be the same as for compensated cirrhosis with detectable HBV DNA
Decompensated cirrhosis 0.34 0.25 0.39 Ossa et al. [58]*
HCC 0.36 0.28 0.41 Ossa et al. [58]*
Liver transplant 0.56 0.49 0.62 Ossa et al. [58]*
Posttransplant 0.67 0.59 0.73 Ossa et al. [58]*
*Utilities from the study by Ossa et al. comprise standard gamble valuations by a sample of 93 UK patients with CHB [58,59].
CHB, chronic hepatitis B; CI, conﬁdence interval; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma.
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sensitivity analysis [62], in which all model parameters except
unit costs were varied over distributions deﬁned by the mean and
95% conﬁdence intervals shown in Tables 2–4 and Appendices
1–2. Costs and relative risks were assumed to follow gamma
distributions, while utilities and probabilities were assigned beta
distributions, in line with best practice [62,63]. Further details of
the distributions used are available on request. In each of the
6500 simulations generated, values for all model parameters
were randomly sampled from their distributions, and the costs,
QALYs, and net beneﬁts for each treatment strategy were calcu-
lated. The proportion of simulations in which the treatment
strategy(ies) in question had the highest total net beneﬁt is
presented.
Results
Treatment strategies involving ﬁrst-line use of TDF generated
more QALYs than strategies involving ﬁrst-line use of any other
nucleos(t)ide (Table 5, Fig. 2). In addition to being more effec-
tive than ﬁrst-line use of ETV or any combination therapy
strategies, ﬁrst-line TDF was also less costly than these treat-
ment strategies.
The net beneﬁt approach provides a useful mechanism for
identifying which treatment strategy is most cost-effective out of
a large number of alternative treatment strategies that may be
used to treat the same population. Results were analyzed at
several different ceiling ratios because of uncertainty about soci-
ety’s willingness to pay for health gains.
Strategies involving ﬁrst-line use of TDF produced the highest
net beneﬁts at all ceiling ratios over £19,084/QALY gained,
demonstrating that ﬁrst-line TDF is the most cost-effective strat-
egy for managing CHB if the NHS is willing to pay at least
£19,084/QALY gained. Except where LAM was used ﬁrst line,
the choice of a second- or third-line agent had minimal impact on
costs or beneﬁts (Table 5). Nevertheless, the model suggests that
adding in or switching to LAM may be the most cost-effective
treatment for any patients who may, in the future, develop TDF
resistance. For brevity, results are only presented for the most
cost-effective or widely used treatments (Table 5; Fig. 2).
First-line use of TDF was found to dominate ADV then LAM
and ﬁrst-line use of ETV or any of the combination therapies
evaluated, being less costly and more effective. Furthermore,
ﬁrst-line TDF and LAM showed extended dominance (more
effective with a lower cost-effectiveness ratio) over all strategies
in which use of ADV, ETV, or combination therapy was delayed
until after LAM resistance has developed. In other words, ﬁrst-
line TDF generated greater health beneﬁts and had lower cost-
effectiveness ratios (relative to LAM followed by BSC) than these
treatments.
First-line TDF was found to cost £19,084/QALY gained rela-
tive to LAM then TDF, which comprised the next most effective
strategy that is not dominated by any other treatment.
Based on the costs and beneﬁts of strategies in which LAM is
used ﬁrst line, TDF monotherapy was also found to be the most
cost-effective treatment for patients who have already developed
LAM resistance. In this patient group, TDF produced higher net
Table 5 Results of the base-case analysis for the 20 most commonly used or most cost-effective treatment strategies
Treatment strategy
Total QALYs/
patient
Total cost/
patient
Cost/QALY
vs. LAM
then BSC
Cost/QALY
vs. LAM
then ETV
Cost/QALY vs.
next most
effective strategy
on frontier*
Total net
beneﬁt at a
£10,000
ceiling ratio
Total net
beneﬁt at a
£20,000
ceiling ratio
Total net
beneﬁt at a
£30,000
ceiling ratio
Strategies that would lie on the cost-effectiveness frontier* if BSC and LAM–BSC are considered to be relevant comparators
BSC 9.18 £11,189 — — — £80,574 £172,338 £264,101
LAM then BSC 9.56 £14,877 — — £9,636 £80,714 £176,304 £271,895
LAM then TDF 10.68 £30,614 £14,064 £2,098 £14,064 £76,166 £182,946 £289,726
TDF then LAM 11.17 £39,914 £15,587 £8,480 £19,084 £71,739 £183,393 £295,046
TDF then TDF + LAM 11.19 £40,610 £15,747 £8,827 £24,992 £71,322 £183,254 £295,186
TDF then TDF + LAM then ETV 11.19 £40,612 £15,748 £8,829 £38,474 £71,320 £183,252 £295,185
Other strategies dominated by treatment pathways on the cost-effectiveness frontier*
TDF then BSC† 11.16 £39,844 £15,630 £8,484 — £71,720 £183,285 £294,850
TDF then ETV‡ 11.17 £40,268 £15,776 £8,731 — £71,418 £183,103 £294,789
LAM then ETV†§ 9.87 £28,915 £45,398 — — £69,768 £168,451 £267,133
LAM then ADV†|| 10.27 £31,129 £22,727 £5,456 — £71,612 £174,354 £277,096
ADV then LAM¶|| 10.53 £40,771 £26,614 £17,863 — £64,549 £169,869 £275,189
LAM then TDF + LAM† 10.85 £38,774 £18,546 £10,068 — £69,702 £178,177 £286,653
LAM then ADV + LAM¶|| 10.51 £43,624 £30,208 £22,897 — £61,483 £166,590 £271,696
ADV then TDF¶ 10.77 £45,327 £25,075 £18,132 — £62,407 £170,141 £277,876
ADV then TDF + LAM¶ 10.82 £47,878 £26,113 £19,866 — £60,350 £168,578 £276,807
ADV then ADV + LAM¶ 10.74 £49,071 £29,022 £23,195 — £58,302 £165,674 £273,047
ETV then LAM¶ 11.03 £52,082 £25,220 £19,869 — £58,261 £168,604 £278,946
ETV then TDF¶ 11.10 £53,429 £24,958 £19,842 — £57,608 £168,645 £279,683
ADV + LAM then TDF + LAM¶ 10.78 £54,735 £32,513 £28,166 — £53,115 £160,964 £268,814
ETV + ADV then LAM¶ 11.09 £88,206 £47,877 £48,503 — £22,701 £133,607 £244,514
*The cost-effectiveness frontier links all the treatments that are not dominated by other options (by either strong or extended dominance) and are therefore potentially cost-effective. Strong
dominance means that the treatment in question is less costly and more effective than its comparator, while extended dominance means that the treatment in question is more effective and
has lower cost-effectiveness ratios than its comparator [73].
†First-line use of TDF and LAM shows extended dominance [73] over this treatment strategy, because TDF then LAM generates more QALYs and has a lower incremental cost-effectiveness
ratio compared with LAM then BSC than this strategy.
‡TDF then LAM and TDF then TDF + LAM show extended dominance over this strategy.
§Second-line use of TDF (in LAM-resistant patients) and LAM then BSC shows extended dominance [73] over this treatment strategy, because LAM then TDF generates more QALYs and has
a lower incremental cost-effectiveness ratio compared with LAM then BSC than this strategy.
||Second-line use of TDF (in LAM-resistant patients) shows strong dominance over this treatment strategy, because it is less costly and generates more QALYs.
¶First-line use of TDF shows strong dominance over this treatment strategy, because it is less costly and generates more QALYs.
A mixed cohort of patients with HBeAg-positive or -negative disease with/without compensated cirrhosis was considered.All results are per patient and are discounted at a rate of 3.5% per
annum.The highest net beneﬁts at each threshold are shown in bold typeface.
ADV, adefovir; BSC, best supportive care; ETV, entecavir; LAM, lamivudine; QALY, quality-adjusted life-year;TDF, tenofovir disoproxil fumarate.
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beneﬁts than second-line use of ETV, ADV, ADV plus LAM, and
cost £14,064/QALY gained compared with giving no second-line
treatment and £2098/QALY compared with second-line use of
ETV (Table 5).
Rerunning the results for speciﬁc patient subgroups demon-
strated that ﬁrst-line use of TDF is the most cost-effective nucleo-
s(t)ide strategy for HBeAg-positive and HBeAg-negative patients,
and for patients with and without compensated cirrhosis at
ceiling ratios of £22,200/QALY and above (Table 6).
Extensive one-way sensitivity analyses were conducted by
varying all model parameters over their 95% conﬁdence intervals
or the range of values shown in the literature (Fig. 3); ranges are
shown in Tables 2–4 and Appendices 1–2 (available at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH13i8_
Dakin.asp). One-way sensitivity analyses focused on the compari-
son between TDF then LAM versus LAM then BSC, because this
comparison is likely to bemost sensitive to changes in the assump-
tions: if TDF remains cost-effective comparedwith LAM then BSC
when the assumptions and data inputs are varied, the conclusion
that TDF is cost-effective relative to all other comparators is also
likely to be robust. These analyses demonstrated that only one
individual model input could cause ﬁrst-line TDF (followed by
LAM) to costmore than £30,000/QALY relative to LAMfollowed
by BSC when varied over the range of values that it was likely to
take (Fig. 3): if the probability of HBeAg-negative patients devel-
oping cirrhosis was reduced to its minimum value (0.4%/year),
this cost-effectiveness ratio increased to £35,096/QALY.
Further sensitivity analyses investigated cost-effectiveness in
speciﬁc situations (Table 6). This demonstrated that the results
are sensitive to the time horizon used in the analysis: when all
costs and beneﬁts occurring more than 19 years in the future
(including years of life lost because of deaths that occurred soon
after start of treatment) were excluded from the model, no treat-
ments (including either ﬁrst- or second-line use of TDF) were
cost-effective relative to LAM then BSC at a £20,000/QALY
threshold. This suggests that for patients with a life expectancy of
less than 19 years, no treatment beyond LAM then BSC would be
cost-effective. Nevertheless, no other sensitivity analyses changed
the conclusions of the analysis.
Probabilistic sensitivity analysis conﬁrmed that TDF then
LAM generates the highest net beneﬁts at a £20,000 to £30,000/
QALY ceiling ratio. At a £20,000/QALY ceiling ratio, there was
a 0.46 probability that TDF is the most cost-effective ﬁrst-line
nucleos(t)ide, and a 0.25 probability that it is most cost-effective
to give LAM followed by TDF. Nevertheless, if society is willing
to pay £30,000/QALY, the probability that ﬁrst-line TDF is the
most cost-effective strategy for managing CHB increases to 0.78.
By contrast, the probability that ﬁrst-line ETV is the most cost-
effective treatment at a £30,000/QALY ceiling ratio approaches
zero. First-line tenofovir showed strong dominance over ﬁrst-line
ETV in 76% of probabilistic simulations, and showed strong or
extended dominance over LAM followed by tenofovir in 47%.
Discussion
This economic evaluation demonstrates that ﬁrst-line use of TDF
is the most cost-effective strategy for managing CHB with
nucleos(t)ides if the NHS is willing to pay at least £19,084 per
QALY gained. Because treatments costing no more than £20,000
to £30,000 per QALY gained are generally considered to be
cost-effective [24], TDF should be considered a highly cost-
effective treatment option for CHB. Furthermore, ﬁrst-line TDF
was also more effective and less costly than ﬁrst-line ETV, and
showed extended dominance over ADV followed by LAM and
over strategies reserving ADV, ETV, or combination therapy until
after LAM resistance develops.
TDF also generated the greatest net beneﬁts of all treatments
that may be considered appropriate salvage therapy for patients
who have already developed LAM resistance. TDF was cost-
effective at a £30,000/QALY threshold in all subgroups
£0
£10,000
£20,000
£30,000
£40,000
£50,000
£60,000
£70,000
£80,000
£90,000
£100,000
9.0 9.5 10.0 10.5 11.0 11.5
Discounted lifetime QALYs per patient
D
is
co
u
n
te
d
 li
fe
ti
m
e 
co
st
 p
er
 p
at
ie
n
t
BSC
LAM then BSC
LAM then ETV
LAM then ADV
LAM then TDF
1st line TDF
ETV+ADV then LAM
1st line ETV
LAM then ADV+LAM
£9,636/QALY
£14,064/QALY
£19,084/QALY
Figure 2 Scatter graph plotting total costs against total QALYs for 20 treatment strategies. Because the choice of second- or third-line agent had minimal impact
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investigated, and the conclusions remained robust in extensive
sensitivity analyses.
The base-case analysis included all plausible nucleos(t)ide
treatment strategies for managing CHB, and demonstrated that
ﬁrst-line use of TDF is the most cost-effective strategy of all those
considered, generating highest net beneﬁts at a £20,000 to
£30,000/QALY threshold. Although LAM followed by BSC may
be cost-effective at lower willingness-to-pay thresholds, it is now
not used in the UK because it is clinically inferior to other
strategies and is not recommended in clinical treatment
guidelines [2].
This analysis focused on comparing the costs and beneﬁts of
nucleos(t)ides, and did not assess the cost-effectiveness of nucleo-
s(t)ides relative to (peg)interferon-alpha. Previous economic
evaluations comparing nucleos(t)ides with interferons have
reported conﬂicting results [12,57,64,65]. Although interferon
and peginterferon are effective treatments for some patients with
CHB, they are typically used only as initial treatment for a
speciﬁc subset of patients (most commonly those with HBeAg-
positive CHB) who are willing and able to tolerate the side effects
of treatment. By contrast, nucleos(t)ides provide long-term viral
suppression in those patients who are unsuitable for, do not
respond to, or do not tolerate interferon therapy. The current
analysis also excluded LdT, which is rarely used in the UK and is
not recommended by NICE [36]. Nevertheless, because TDF is
less costly [5,66], more potent [11], and has a lower risk of
resistance than LdT [19,67–71], the inclusion of LdT would not
have changed the conclusion that ﬁrst-line TDF is the most
cost-effective nucleos(t)ide strategy for CHB.
Although the net beneﬁt approach is commonly used to
produce cost-effectiveness acceptability curves and analyze
uncertainty [22], the current analysis is, to our knowledge, the
ﬁrst application of the net beneﬁt approach to aid interpretation
of deterministic base-case results from an economic evaluation
considering a large number of comparators. Although the con-
clusions are not affected by the choice of approach, the net
beneﬁt approach simpliﬁes interpretation of results and makes it
substantially easier to identify the optimal strategy and strongly/
extended dominance. Nevertheless, a disadvantage of the net
beneﬁt approach is the need to specify a ceiling ratio and repeat
analyses at alternative threshold values.
Like all model-based economic evaluations, this analysis is
limited by the quality of data available and the assumptions that
were necessary to simplify the analysis. Nevertheless, where pos-
sible, assumptions were based on peer-reviewed journal articles
and were validated by clinical experts. In particular, lack of data
necessitated assumptions about the probability of response, sero-
conversion, or resistance associated with combination therapy or
second-line TDF. The efﬁcacy of TDF in nucleos(t)ide-resistant
patients was also based on a meta-analysis that included trials on
HIV-coinfected patients, as no RCTs of TDF in this indication
have yet been published. Furthermore, as no cases of virological
HBV resistance to TDF have yet been identiﬁed, the resistance
rates used in the model were based on the highest incidence rates
possible, conservatively underestimating the potential beneﬁts
associated with TDF. Transition probabilities were also generally
assumed to be constant over time because of a shortage of data
on how probabilities vary over time; in the absence of such data,
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Figure 3 Impact of different variables on the cost per quality-adjusted life-year (QALY) gained for ﬁrst-line TDF relative to LAM, then best supportive care (BSC).
Each bar represents the range of values for the cost/QALY that would be generated by varying the parameter in question over its likely range or 95% conﬁdence
interval.Variables are ranked in descending order of importance. For clarity, only the 20 variables having most impact on the results are shown in this diagram.The
vertical line shows the base-case value of £15,587/QALY gained. BSC, best supportive care; CC, compensated cirrhosis; CHB, chronic hepatitis B; HBeAg, hepatitis
B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; pts, patients;TDF, tenofovir disoproxil fumarate;VS, viral suppression.
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it is difﬁcult to anticipate what impact this simpliﬁcation may
have had on the results.
The costs used in this analysis were based on clinical practice
in the UK, which limits the extent to which the cost-effectiveness
ratios calculated can be applied to clinical practice in other
settings. Even within the UK, variations in clinical practice and
patient mix may affect the costs and beneﬁts of treatment within
any given region. Nevertheless, ﬁrst-line TDF remained cost-
effective in extensive sensitivity analyses, including when the cost
of all disease states was varied 25%.
At present, there are large regional disparities in the manage-
ment of CHB across the UK, particularly with respect to the
availability of nucleos(t)ides, with many patients currently
receiving no antiviral therapy [72]. Nevertheless, recent NICE
guidance recommending use of TDF [34] may reduce post–code
prescribing and make management of CHB more cost-effective.
Sensitivity analyses suggested that the cost-effectiveness of
TDF depends on the risk of HBeAg-negative patients develop-
ing cirrhosis. The clinical indications for treating HBeAg-
negative CHB are based on a combination of HBV DNA
concentrations, aminotransferase levels, and histology [2]. In
practice, it can be difﬁcult to reliably predict the rate of pro-
gression in patients at this stage of the disease, given the ﬂuc-
tuations in these clinical parameters. Nevertheless, our model
has clinical utility and demonstrates to clinicians the impact of
this variable on the cost-effectiveness of ﬁrst-line TDF. Thus,
clinicians can use the results of this sensitivity analysis to judge
the appropriate timing and indications for treating HBeAg-
negative disease, taking account of the uncertainty around the
rate of disease progression.
Further clinical trials on use of nucleos(t)ide combinations
and use of newer nucleos(t)ides in patients with more severe liver
disease are required to inform future economic evaluations and
to produce more accurate estimates of cost-effectiveness. Addi-
tionally, the cost-effectiveness of nucleos(t)ides in patients coin-
fected with HIV, hepatitis C virus, and/or hepatitis D virus has
not yet been assessed.
Conclusions
Given the threshold cost-effectiveness ratio used in the NHS [24],
ﬁrst-line use of TDF is the preferred treatment for patients with
CHB who are indicated for nucleos(t)ide therapy. In particular,
ﬁrst-line TDF was found to be both more effective and less costly
than ﬁrst-line use of ETV. TDF was also the most cost-effective
treatment for patients who have already developed resistance to
LAM.
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